BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29915956)

  • 1. Generalizability of clinical trials of advanced melanoma in the real-world, population-based setting.
    Sam D; Gresham G; Abdel-Rahman O; Cheung WY
    Med Oncol; 2018 Jun; 35(7):110. PubMed ID: 29915956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study.
    Dalle S; Mortier L; Corrie P; Lotem M; Board R; Arance AM; Meiss F; Terheyden P; Gutzmer R; Buysse B; Oh K; Brokaw J; Le TK; Mathias SD; Scotto J; Lord-Bessen J; Moshyk A; Kotapati S; Middleton MR
    BMC Cancer; 2021 May; 21(1):642. PubMed ID: 34051732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers.
    Joseph RW; Shillington AC; Lee TA; Macahilig CP; Diede SJ; Dave V; Harshaw Q; Scherrer E; Liu FX
    J Med Econ; 2020 Feb; 23(2):132-138. PubMed ID: 31750751
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study.
    Urun Y; Yasar HA; Turna H; Esin E; Sedef AM; Alkan A; Oksuzoglu B; Ozdemir N; Sendur MN; Sezer A; Kılıckap S; Utkan G; Akman T; Akbulut H; Celik I; Abalı H
    J Oncol Pharm Pract; 2019 Oct; 25(7):1658-1664. PubMed ID: 30400750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up.
    Aamdal E; Jacobsen KD; Straume O; Kersten C; Herlofsen O; Karlsen J; Hussain I; Amundsen A; Dalhaug A; Nyakas M; Schuster C; Hagene KT; Holmsen K; Russnes HG; Skovlund E; Kaasa S; Aamdal S; Kyte JA; Guren TK
    Int J Cancer; 2022 Jan; 150(1):100-111. PubMed ID: 34449877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival of melanoma patients treated with novel drugs: retrospective analysis of real-world data.
    Polkowska M; Ekk-Cierniakowski P; Czepielewska E; Wysoczański W; Matusewicz W; Kozłowska-Wojciechowska M
    J Cancer Res Clin Oncol; 2017 Oct; 143(10):2087-2094. PubMed ID: 28608286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.
    Cassidy MR; Wolchok RE; Zheng J; Panageas KS; Wolchok JD; Coit D; Postow MA; Ariyan C
    EBioMedicine; 2017 Apr; 18():56-61. PubMed ID: 28356222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.
    Jochems A; Leeneman B; Franken MG; Schouwenburg MG; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; van den Eertwegh AJM; Groenewegen G; de Groot JWB; Haanen JBAG; Hospers GAP; Kapiteijn E; Koornstra RH; Kruit WHJ; Louwman MWJ; Piersma D; van Rijn RS; Ten Tije AJ; Vreugdenhil G; Wouters MWJM; Uyl-de Groot CA; van der Hoeven KJM
    Anticancer Drugs; 2018 Jul; 29(6):572-578. PubMed ID: 29659371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma.
    Amin A; Lawson DH; Salama AK; Koon HB; Guthrie T; Thomas SS; O'Day SJ; Shaheen MF; Zhang B; Francis S; Hodi FS
    J Immunother Cancer; 2016; 4():44. PubMed ID: 27532019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
    Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
    Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
    Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
    Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.
    Moser JC; Chen D; Hu-Lieskovan S; Grossmann KF; Patel S; Colonna SV; Ying J; Hyngstrom JR
    Cancer Med; 2019 Dec; 8(18):7637-7643. PubMed ID: 31677253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world, population-based cohort study of toxicity and resource utilization of second-line ipilimumab for metastatic melanoma in Ontario, Canada.
    Dai WF; Beca J; Croxford R; Isaranuwatchai W; Menjak IB; Petrella TM; Mittmann N; Earle CC; Gavura S; Mercer RE; Hanna TP; Chan KKW
    Int J Cancer; 2021 Apr; 148(8):1910-1918. PubMed ID: 33105030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of BRAF inhibitors and anti-CTLA4 antibody in melanoma patients-real-world data.
    Polkowska M; Ekk-Cierniakowski P; Czepielewska E; Kozłowska-Wojciechowska M
    Eur J Clin Pharmacol; 2019 Mar; 75(3):329-334. PubMed ID: 30386910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The real-world impact of modern treatments on the survival of patients with metastatic melanoma.
    Donia M; Ellebaek E; Øllegaard TH; Duval L; Aaby JB; Hoejberg L; Køhler UH; Schmidt H; Bastholt L; Svane IM
    Eur J Cancer; 2019 Feb; 108():25-32. PubMed ID: 30605822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma.
    Drysdale E; Peng Y; Nguyen P; Baetz T; Hanna TP
    Melanoma Res; 2019 Dec; 29(6):635-642. PubMed ID: 30789386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab.
    Mohr P; Ascierto P; Arance A; McArthur G; Hernaez A; Kaskel P; Shinde R; Stevinson K
    J Eur Acad Dermatol Venereol; 2018 Jun; 32(6):962-971. PubMed ID: 29044660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada.
    Dai WF; Beca JM; Croxford R; Isaranawatchai W; Menjak IB; Petrella TM; Mittmann N; Earle CC; Gavura S; Hanna TP; Chan KKW
    BMC Cancer; 2020 Apr; 20(1):304. PubMed ID: 32293341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
    Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
    Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
    Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.